Research Article: Clinical Efficacy and Safety Evaluation of Ceftazidime-Avibactam in the Treatment of Klebsiella pneumoniae Infection: A Retrospective Analysis from a Hospital in China
Abstract:
Despite continuous improvement in living standards worldwide, infectious diseases remain a topic of public health concern. In recent years, the pandemic coronavirus disease (COVID-) has led people to pay more attention to preventing and controlling infectious diseases. In addition to viral infections such as COVID-, bacterial infections cause many human diseases; the emergence and continuous evolution of drug-resistant bacteria especially creates great difficulties in clinical treatment. In particular, the incidence of carbapenem-resistant organism (CRO) infections has shown a significant upward trend, which has become one of the major challenges in the medical field. The production of carbapenemases plays an essential role in carbapenem resistance. Since the genes that encode carbapenemases are located on plasmids and other mobile genetic elements, the determinants of carbapenem resistance have rapidly spread in many regions of the world. Data presented in Zhejiang Province, China, indicate that the prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) has increased from .% in to .% in , and this trend is further increasing among ICU patients., In addition, for patients with indwelling catheters, biofilm formation is another important mechanism of drug resistance in Klebsiella pneumoniae (KP)., Previous studies have shown that Ethylenediaminetetraacetic acid (EDTA) can be used as an adjuvant against biofilms, and it has synergistic antibacterial effects with aztreonam, colistin, and ceftazidime-avibactam (CAZ-AVI).–
Introduction:
Despite continuous improvement in living standards worldwide, infectious diseases remain a topic of public health concern. In recent years, the pandemic coronavirus disease (COVID-) has led people to pay more attention to preventing and controlling infectious diseases. In addition to viral infections such as COVID-, bacterial infections cause many human diseases; the emergence and continuous evolution of drug-resistant bacteria especially creates great difficulties in clinical treatment. In particular, the…
Read more